Sansheng Pharmaceuticals welcomed the heavyweight good performance is expected to reach a new high

Recently, Sansheng Pharmaceuticals announced that Baidayan ® has been officially approved by the CFDA, becoming the first long-acting GLP-1-1 patient agonist approved for the treatment of type 2 diabetes. In addition, Sansheng Pharmaceuticals, as a leading company in the domestic biopharmaceutical industry, has a market-leading biopharmaceutical product line in oncology, autoimmune diseases and kidneys, and its products include Teo, Ibio, Isaipe, etc., which maintain a leading position in the domestic market.The first long-acting GLP-1 in China was approved for listing
This time, Sansheng Pharmaceuticals was approved for listing long-acting GLP-1 (glutatroglycope-like peptide-1) is a sugar-lowering drug that can be given once a week, the product name is Bydureon® ®, the generic name is injectable Essena peptide microcoste, for the treatment of type 2 diabetes, It is the first long-acting GLP-1-subjector astrogen approved in China.
Currently, five GLP-1 perturbants have been approved for the market, including AstraZeneta Productions, Sansheng Pharmaceuticals, which sells and promotes Baxta (Essena peptide) and Baedayan (Essena peptide microspheres), No and Nord's Noheli (Lilalutide), Sanofi's Lismin (Lisna peptide), and Shanghai Renren Bioseed (Benaruptide).
addition, three other long-acting varieties are also being declared, including polyglycol locena peptides in Howson, Jiangsu Province, Lilly's lactose peptides, noro and Nord's Somatropeptides. Jiangsu Haussen submitted a production application for polyglycol locena peptide in December 2017 or will be approved by the end of 2018.is rich in research product line
Sansheng Pharmaceuticals is a biopharmaceutical group that combines the research and development, production and sale of biopharmaceuticals, and is one of the first Chinese biopharmaceutical companies to land on the U.S. stock market. Subsequently, with the restructuring of the Group's development strategy, it was listed in Hong Kong in 2015 after privatization in the United States and is now valued at nearly HK$40 billion.
Sansheng Pharmaceuticals focuses on the development of recombinant or genetically engineered protein drugs, monoclonal antibodies to meet the needs of clinical treatment of kidney disease, tumors, autoimmune diseases, anti-organ transplant rejection and other major diseases. In the first half of 2017, Sansheng Pharmaceuticals' research and development costs were 113 million yuan, up 3.7% from 109 million yuan a year earlier, accounting for 6.62% of revenue, compared with 7.56% for Fosun Pharma and 4.51% for Stone Pharmaceutical Group.
, Sansheng Pharmaceuticals has more than 20 products under research, covering oncology, autoimmune diseases and other diseases, nephrology, metabolism and dermatology and other fields, of which 16 are new drugs of the national class. It is reported that Sansheng Pharmaceutical Qutozhu, Lytoxi two monoantigen has completed clinical trials, QutoZhu is expected to be reported in the first half of 2018, the second half of 2018 or 2019 on the market.Seat core products to maintain market leadership
According to the annual report, Sansheng Pharmaceuticals has several core products such as Teo, Isepp, Ebio, etc. have continued to maintain the leading position in the domestic market.
is a patented product independently developed by Sansheng Pharmaceuticals, which became the world's only commercially recombinant human plateplate production product after its launch in 2006. Tebio has been approved for two types of adaptive disorders: the treatment of plate reduction caused by chemotherapy and the treatment of immunocompetitive plate plateboard reduction cyanosis. According to Minenet data, in 2016, china's public medical institutions terminals (including China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals) Tybi Australia sales exceeded the 1 billion mark, about 1.05 billion yuan, an increase of 25.04 percent year-on-year. In addition, the 2017 edition of the National Health Insurance Directory removes the limit on plateplate reduction due to chemotherapy treatment in Tybi Australia, and overall sales growth in Tybi Australia is expected to rise again.
, commonly known as Inasip, is a recombinant human type II tumor necrotizing factor-antibody fusion protein produced by subsidiary Sansheng Guojian. First introduced in China in 2005 for the treatment of rheumatoid arthritis, severe spina bifia and psoriasis. Isaipe has been included in the 2017 National Health Care Directory. According to Milnet data, in 2016 China's public medical institutions terminal Isaipe sales reached 730 million yuan, up 15.20% YoY, the market share of 94.88 percent, ranked first.
Ibio is a CFDA-approved recombined human erythrocytople progenitor (rhEPO) product for three adaptive disorders: anemia caused by chronic kidney disease, anemia caused by chemotherapy, and red blood cell mobilization during surgical peri-surgery. Ybio has been a dominant leader in China's rhEPO market since 2002, with terminal sales of 1.15 billion yuan and a market share of 42.4% in 2016. In addition, Saibor is the second brand of Sansheng Pharmaceutical RhEPO products, produced by subsidiary Shenzhen Saibao Biopharmaceuticals, with terminal sales of 120 million yuan in 2016 in China's public medical institutions.conclusion,
from the information disclosed publicly by Sansheng Pharmaceuticals, Sansheng Pharmaceuticals has seen steady growth in performance in recent years. In the first half of 2017 alone, revenue was approximately RMB1,707 million, net profit was RMB390 million and gross profit was RMB1,457 million, up approximately 30.8%, 34.3% and 28.6% YoY from 2016. Getting such a welcome performance must be indescent from several of its core products. And this time, The listing of ® can open up new sources of profit for Sansheng Pharmaceuticals? Let's wait and see! (Mi Net)